Publications

(Displaying in Reverse Chronological Order)

2596
Singh S, Mariappan TT, Sharda N and Singh B. Degradation of rifampicin, isoniazid, and pyrazinamide from prepared mixtures and marketed single and combination products in acid conditions Pharmacy and Pharmacology Communications 2000, 6, 491-494.
2597
Singh S, Mariappan TT, Sharda N, Kumar S and Chakraborti AK. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions Pharmacy and Pharmacology Communications 2000, 6, 405-410.
2598
Verma RK, Mishra B and Garg S. Osmotically controlled oral drug delivery Drug Development and Industrial Pharmacy 2000, 26, 695-708.
2599
Vermani K and Garg S. The scope and potential of vaginal drug delivery Pharmaceutical Science & Technology Today 2000, 3, 359-364.
2600
2601
Chakraborti AK, Basak (nee Nandi) A and Grover V. Chemoselective protection of carboxylic acid as methyl ester: A practical alternative to diazomethane protocol Journal of Organic Chemistry 1999, 64, 8014-8017.
2602
Chakraborti AK, Nayak MK and Sharma L. Selective Deprotection of Aryl Acetates, Benzoates, Pivalates, and Tosylates under Nonhydrolytic and Virtually Neutral Conditions Journal of Organic Chemistry 1999, 64, 8027-8030.
2603
Gandhi R, Kaul CL and Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms Pharmaceutical Science & Technology Today 1999, 2, 160-170.
2604
Jaiswal J, Ramarao P and Panchagnula R. Transdermal delivery of naloxone: ex vivo permeation studies International Journal of Pharmaceutics 1999, 179, 129-134.
2605
Kaul CL. Role of sympathetic nervous system in experimental hypertension and diabetes mellitus Clinical and Experimental Hypertension 1999, 21, 95-112.
2606
Panchagnula R, Anand BD, Kaur K, Singh I and Kaul CL. Determination of Paclitaxel in Human Plasma by HPLC Pharmacy and Pharmacology Communications 1999, 5, 587-589.
2607
Panchagnula R, Kaur KJ, Singh I and Kaul CL. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO International Journal of Tuberculosis and Lung Disease 1999, 3, S336-S342..
2608
Panchagnula R, Singh I, Kaur KJ and Kaul CL. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations Methods and Findings in Experimental and Clinical Pharmacology 1999, 21, 625-628.
2609
Panchagnula R, Sood A, Sharda N, Kaur K and Kaul CL. Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method Journal of Pharmaceutical and Biomedical Analysis 1999, 18, 1013-1020.
2610
Rajnikant, Gupta VK, Goswami KN, Magotra DK, Bhutani KK and Gupta DK. Crystal stucture of 4,5-dihydro-6H-tetrazolo [1,5-a]-1-benzazepine, C10H10N4 New Crystal Structures 1999, 214, 377-378.